Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do RSV vaccines work as well in nursing homes? new study investigates

NCT ID NCT06077149

Vaccine Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how well licensed RSV vaccines (Pfizer's Abrysvo or GSK's Arexvy) trigger an immune response in adults over 60 living in long-term care facilities compared to those living independently in the community. Researchers measured antibody levels before and 30 days after vaccination in 152 participants. The goal is to see if these vaccines protect vulnerable nursing home residents as effectively as they protect community-dwelling older adults.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RSV vaccine (Pfizer's Abrysvo or GSK's Arexvy)
What this could lead to
If successful, this could show that RSV vaccines protect older adults in nursing homes as well as they protect those living independently.
What could go wrong
This is a small, completed Phase 4 study (152 participants) comparing immune responses, not preventing illness. Results may not apply to all older adults or predict real-world protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

152 people

The number who actually took part.

Started

Nov 2023

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥60 years of age who live in skilled nursing facilities or reside independently in the community * Life expectancy of \>6 months, as assessed by the investigator * Able to sign informed consent or to provide consent via a legally authorized representative (LAR) Exclusion Criteria: * History of a current immunosuppressive condition or receipt of chemotherapy or other immunosuppressive or cytotoxic therapy, including chronic prednisone use of ≥ 20 mg/day for more than 14 days within 3 months of study vaccination * History of hypersensitivity or reaction to any vaccine component * Simultaneous administration of another vaccine (influenza, SARS-CoV-2) or within a 14-day window before or after intervention * Previous receipt or intended receipt of an RSV vaccine outside the study * Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration. * Documented RSV infection within 2 months prior to study intervention.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Respiratory syncytial virus (RSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Respiratory syncytial virus (RSV)

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.